• 1. Capsaicin presynaptically inhibits glutamate release through the activation of TRPV1 and calcineurin in the hippocampus of rats
  Cheng Wei Lu,Tzu Yu Lin,Ting Yang Hsie,Shu Kuei Huang,Su Jane Wang Food Funct. 2017 8 1859
• 2. TCD, a triterpenoid isolated from wild bitter gourd, reduces synaptosomal release of glutamate and protects against kainic acid-induced neuronal death
  Szu Kai Hsu,Chi Feng Hung,Hsiao Ching Yang,Jing Ru Weng,Su Jane Wang Food Funct. 2020 11 9858
• 3. Inhibition of N-type calcium ion channels by tricyclic antidepressants – experimental and theoretical justification for their use for neuropathic pain
  Fernanda C. Cardoso,Matthieu Schmit,Michael J. Kuiper,Richard J. Lewis,Kellie L. Tuck,Peter J. Duggan RSC Med. Chem. 2022 13 183
• 4. Supramolecular assemblies of multifunctional microgels for biomedical applications
  Jingxia Zheng,Canjie Zhu,Xun Xu,Xinwei Wang,Jun Fu J. Mater. Chem. B 2023 11 6265

• Solvents and Organic Chemicals Organic Compounds Organic Polymers Polypeptides Polypeptides
• Solvents and Organic Chemicals Organic Compounds Organic Polymers Polypeptides

Professional Introduction to omega-Conotoxin GVIA (Marine Snail, Conus geographus) (N-type Blocker) and CAS No. 106375-28-4

omega-Conotoxin GVIA (Marine Snail, Conus geographus) (N-type Blocker), identified by the Chemical Abstracts Service Number (CAS No.) 106375-28-4, is a highly specific and potent peptide derivative derived from the venom of the marine snail Conus geographus. This compound has garnered significant attention in the field of pharmacology and neuroscience due to its unique mechanism of action as an N-type voltage-gated calcium channel blocker. Over the years, extensive research has been conducted to elucidate its therapeutic potential, particularly in the management of chronic pain and neurodegenerative disorders.

The structure of omega-Conotoxin GVIA consists of a 25-amino acid sequence that exhibits remarkable selectivity for N-type calcium channels, which are predominantly expressed in central and peripheral neurons. This selectivity is attributed to its specific arrangement of disulfide bonds and hydrophobic residues, which interact precisely with the pore region of the N-type channel. The compound's ability to selectively block these channels has made it a subject of intense study for its potential applications in treating conditions characterized by excessive neuronal excitability.

In recent years, preclinical studies have demonstrated the promising role of omega-Conotoxin GVIA in modulating pain signaling pathways. Unlike traditional analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) or opioids, which often target broader receptor systems and may lead to side effects like tolerance and dependence, omega-Conotoxin GVIA offers a more targeted approach. By selectively inhibiting N-type calcium channels, it reduces the release of neurotransmitters such as glutamate and substance P, which are key mediators of pain transmission.

The therapeutic potential of CAS No. 106375-28-4 has been further explored in models of neuropathic pain, where chronic injury or disease leads to hyperexcitability of sensory neurons. Studies have shown that administration of omega-Conotoxin GVIA can significantly attenuate pain behavior in animal models without causing motor impairments or sedation. This highlights its potential as a safer alternative for pain management compared to existing pharmacological agents.

In addition to its role in pain modulation, research has also investigated the neuroprotective effects of omega-Conotoxin GVIA. N-type calcium channels are implicated in various neurological disorders, including epilepsy, stroke, and neurodegenerative diseases such as Alzheimer's and Parkinson's. By blocking these channels, CAS No. 106375-28-4 may help mitigate excessive neuronal activity that contributes to cell death and tissue damage. Preliminary findings suggest that it could protect against excitotoxicity-induced neuronal death, offering a novel strategy for neuroprotection.

The synthesis and purification of omega-Conotoxin GVIA have been refined over time, enabling researchers to produce high-purity samples for both academic and commercial purposes. Advances in solid-phase peptide synthesis have made it possible to obtain large quantities of this peptide with minimal batch-to-batch variability. Furthermore, techniques such as recombinant DNA technology have been employed to enhance the production scalability and cost-effectiveness of this compound.

The pharmacokinetic properties of CAS No. 106375-28-4 have also been thoroughly studied to optimize its therapeutic efficacy. Initial studies indicated that the compound exhibits rapid onset and short duration of action when administered intrathecally or locally within the nervous system. However, systemic administration poses challenges due to its hydrophobic nature and susceptibility to enzymatic degradation. Efforts are ongoing to develop formulations that can prolong its bioavailability while maintaining its potency.

The safety profile of omega-Conotoxin GVIA has been evaluated through multiple preclinical trials, revealing a favorable tolerability profile with minimal side effects at therapeutic doses. However, potential risks associated with its use must be carefully considered, particularly regarding interactions with other medications that affect neuronal function. Ongoing clinical trials aim to provide more comprehensive data on its safety and efficacy in human populations.

The future directions for research on CAS No. 106375-28-4 include exploring novel delivery systems that can enhance its bioavailability and reduce off-target effects. Nanotechnology-based approaches have shown promise in improving the delivery efficiency of peptides by protecting them from degradation and targeting them specifically to affected tissues. Additionally, computational modeling techniques are being utilized to design analogs with enhanced pharmacological properties.

In conclusion, omega-Conotoxin GVIA (Marine Snail, Conus geographus) (N-type Blocker), identified by CAS No. 106375-28-4, represents a significant advancement in the field of neuropharmacology due to its selective targeting of N-type calcium channels. Its potential applications in managing chronic pain, neuropathic conditions, and neurodegenerative diseases make it a compelling candidate for further clinical development. As research continues to uncover new insights into its mechanisms of action and pharmacokinetic properties, this compound holds promise for improving therapeutic outcomes in patients suffering from neurological disorders.

• 50-57-7(Lysipressin)
• 147794-23-8(omega-Conotoxin MVIIC (P/Q-type Blocker))
• 16679-58-6(Desmopressin)
• 9034-50-8(Vasotocin)
• 9087-70-1(Aprotinin)
• 115966-23-9(Urodilatin)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)